Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Triglycerides are carried in the bloodstream as the components of very low-density lipoproteins and chylomicrons. These circulating triglycerides are primarily hydrolyzed in muscle and adipose tissue by the enzyme lipoprotein lipase (LPL). The activity of LPL is regulated by numerous mechanisms, including by three members of the angiopoietin-like protein family: ANGPTL3, ANGPTL4, and ANGPTL8. In this review, we discuss the recent literature concerning the role and mechanism of action of ANGPTL4 in lipid metabolism. ANGPTL4 is a fasting- and lipid-induced factor secreted by numerous cells, including adipocytes, hepatocytes, (cardio)myocytes, and macrophages. In adipocytes, ANGPTL4 mediates the fasting-induced repression of LPL activity by promoting the unfolding of LPL, leading to the cleavage and subsequent degradation of LPL. The inhibition of LPL by ANGPTL4 is opposed by ANGPTL8, which keeps the LPL active after feeding. In macrophages and (cardio)myocytes, ANGPTL4 functions as a lipid-inducible feedback regulator of LPL-mediated lipid uptake. In comparison, in hepatocytes, ANGPTL4 functions as a local inhibitor of hepatic lipase and possibly as an endocrine inhibitor of LPL in extra-hepatic tissues. At the genetic level, loss-of-function mutations in ANGPTL4 are associated with lower plasma triglycerides and higher plasma HDL-C levels, and a reduced risk of coronary artery disease, suggesting that ANGPTL4 is a viable pharmacological target for reducing cardiovascular risk. Whole-body targeting of ANGPTL4 is contraindicated because of severe pathological complications, whereas liver-specific inactivation of ANGPTL4, either as monotherapy or coupled to anti-ANGPTL3 therapies might be a suitable strategy for lowering plasma triglycerides in selected patient groups. In conclusion, the tissue-specific targeting of ANGPTL4 appears to be a viable pharmacological approach to reduce circulating triglycerides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown adipose tissue activity controls triglyceride clearance
Bartelt, A., Bruns, O. T., Reimer, R., Hohenberg, H., Ittrich, H., Peldschus, K., Kaul, M. G., Tromsdorf, U. I., Weller, H., Waurisch, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2297 · Cited by 1,608 · cited 1×
“LPL is expressed at high levels in brown adipose tissue (BAT), where it accommodates the high requirement of BAT for lipid fuels during cold (55).”
BackgroundGenetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Romeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2007) · Nature Genetics · doi:10.1038/ng1984 · Cited by 511
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Mandard, S., Zandbergen, F., van Straten, E., Wahli, W., Kuipers, F., Müller, M., & Kersten, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506519200 · Cited by 433
Self-citationKöster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427 · cited 1×
“Earlier studies indicated that the liver-specific overexpression of ANGPTL4 raises plasma TG levels and decreases postheparin plasma LPL activity but does not influence hepatic VLDL secretion (24, 41, 60).”
BackgroundStaiger, H., Haas, C., Machann, J., Werner, R., Weisser, M., Schick, F., Machicao, F., Stefan, N., Fritsche, A., & Häring, H.-U. (2009) · Diabetes · doi:10.2337/db07-1438 · Cited by 183
Koliwad, S. K., Kuo, T., Shipp, L. E., Gray, N. E., Backhed, F., So, A. Y.-L., Farese, R. V., & Wang, J.-C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.025452 · Cited by 164
Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise
Catoire, M., Alex, S., Paraskevopulos, N., Mattijssen, F., Evers-van Gogh, I., Schaart, G., Jeppesen, J., Kneppers, A., Mensink, M., Voshol, P. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400889111 · Cited by 150 · cited 3×
“use of plasma TG as a fuel for active muscles (66).”
BackgroundMethodSelf-citationGray, N. E., Lam, L. N., Yang, K., Zhou, A. Y., Koliwad, S., & Wang, J.-C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.294124 · Cited by 116 · cited 3×
“Conversely, ANGPTL4 deficiency abolishes the fasting-induced increase in plasma nonesterified fatty acids (43, 52, 53).”
BackgroundSingh, A. K., Chaube, B., Zhang, X., Sun, J., Citrin, K. M., Canfrán-Duque, A., Aryal, B., Rotllan, N., Varela, L., Lee, R. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140989 · Cited by 115 · cited 3×
“In favor of the latter mechanism, hepatocyte-specific deficiency of ANGPTL4 markedly increased postheparin plasma hepatic lipase activity, whereas the overexpression of ANGPTL4 decreased postheparin hepatic lipase activity (37, 57).”
BackgroundRegulation of lipoprotein lipase-mediated lipolysis of triglycerides
Basu, D., & Goldberg, I. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000676 · Cited by 114 · cited 15×
“Other data suggest that via intracellular binding of ANGPTL8 to ANGPTL4, ANGPTL8 may promote the degradation of ANGPTL4 in adipocytes (51).”
BackgroundInfluentialAngiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting
Cushing, E. M., Chi, X., Sylvers, K. L., Shetty, S. K., Potthoff, M. J., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.007 · Cited by 88
Angiopoietin-like Protein 4 Inhibition of Lipoprotein Lipase
Lafferty, M. J., Bradford, K. C., Erie, D. A., & Neher, S. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497602 · Cited by 88 · cited 1×
“As an alternative to promoting irreversible LPL unfolding, it has been suggested that ANGPTL4 functions as a reversible, noncompetitive inhibitor of LPL (87).”
BackgroundDijk, W., Ruppert, P. M. M., Oost, L. J., & Kersten, S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002426 · Cited by 72 · cited 7×
“The cleavage of LPL by PCSK3 is triggered by the ANGPTL4-induced unfolding of LPL (46, 47).”
BackgroundInfluentialSelf-citationVienberg, S. G., Kleinridders, A., Suzuki, R., & Kahn, C. R. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.003 · Cited by 33 · cited 1×
“creases LPL activity in skeletal muscles of mice (68).”
Background
Cited by
Advances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
“There is also a term known as “diabetic dyslipidemia”, which refers to elevated levels of TGs, TRLs (triglyceride-rich lipoproteins), and LDL-C while the level of HDL is lowered.”
BackgroundPellegata, N. S., Berriel Diaz, M., Rohm, M., & Herzig, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10058-y · Cited by 33
Therapeutic Potentials of Microalgae and Their Bioactive Compounds on Diabetes Mellitus
Tamel Selvan, K., Goon, J. A., Makpol, S., & Tan, J. K. (2023) · Marine Drugs · doi:10.3390/md21090462 · Cited by 32
Impact of loss-of-function in angiopoietin-like 4 on the human phenome
Gagnon, E., Bourgault, J., Gobeil, É., Thériault, S., & Arsenault, B. J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117558 · Cited by 17
Metadata
- Authors
- Kersten, S.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2021
- Volume
- 62
- Pages
- 100150
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W3211803164
- Cited by
- 145
- References
- 17
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.